-
أخبار
-
أخبار
COMING UP: New TIF Webinar On ”COVID-19 Vaccinations & Patients With Haemoglobin Disorders”
TIF is delighted to inform you that a Special Webinar on ‘’COVID-19 Vaccinations & Patients with Haemoglobin Disorders’’ will take place on Wednesday, 31 March 2021, at 14:30-16:00 EEST/12:30-14:00 GMT.…
أكمل القراءة » -
TIF News (AR)
A Head-to-Head Comparison of BMT, Gene Therapy & Gene Editing Through A Brand New TIF Infographic
The expansion of management options and therapies for patients with thalassaemia is nowadays a reality, thanks to the application of new, revolutionary scientific procedures. However, patients’ understanding on the distinct…
أكمل القراءة » -
TIF Publications
Potentially Curative Approaches for β-Thalassaemia (2021)
A comprehensive infographic with a head-to-head comparison on the most essential aspects of BMT, Gene Therapy & Gene Editing as potentially curative procedures for patients with β-thalassaemia.
أكمل القراءة » -
أخبار
TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required
Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 10%…
أكمل القراءة » -
TIF News (AR)
Out Now: The Latest Issue of TIF’s COVID-19 Vaccinations Update
Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing a…
أكمل القراءة » -
Surveys
Sickle Cell Disease Patients’ Views on Oxbryta
OXBRYTA (voxelotor) is a prescription medicine used for the treatment of sickle cell disease (SCD) and constitutes the first aproved treatment that directly inhibits sickle hemoglobin polymerization, the root cause…
أكمل القراءة » -
أخبار
TIF Supports IAPO´s Call For The Ratification Of The African Medicines Agency Treaty
Two years after the Treaty to establish an African Medicines Agency was agreed, over 40 leading organizations, including the Thalassaemia International Federation (TIF), and hundreds of thousands of patients, researchers…
أكمل القراءة » -
أخبار
TIF’s Submission To The UK NICE’s Consultation Document For Zynteglo®
On February 12, in an appraisal consultation document, the UK National Institute for Health and Care Excellence (NICE) recommended against the use of Bluebird Bio’s Zynteglo (betibeglogene autotemcel) gene therapy for the…
أكمل القراءة » -
Member News
Time To Get Ready For Rare Disease Day 2021!
TIF joins forces with 300 million people around the world for the global observance of Rare Disease Day, coming up on February 28th. Rare Disease Day is an annual awareness…
أكمل القراءة »